Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02515227 · ClinicalTrials.gov registry record · Phase 1
Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab
A Phase 1 study, sponsored by Craig L Slingluff, Jr.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02515227 is a Phase 1 study that has completed, run by Craig L Slingluff, Jr. The registered enrollment target is 22 participants.
The verdict
NCT02515227, a Phase 1 study, has completed, sponsored by Craig L Slingluff, Jr.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study evaluates whether it is safe to administer a peptide vaccine in combination with pembrolizumab. This study will also evaluate the effects of the combination of the peptide vaccine and pembrolizumab on the immune system. The investigators will monitor these effects by performing tests in the laboratory on participants' blood, a lymph node, and tumor samples.
Interventions
- DRUG Pembrolizumab
- BIOLOGICAL 6MHP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-10-06 |
| Est. Completion | 2020-03-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02515227
The ClinicalTrials.gov registry entry for NCT02515227 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Craig L Slingluff, Jr, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02515227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02515227 about?
NCT02515227 is a clinical study titled "Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab". This study evaluates whether it is safe to administer a peptide vaccine in combination with pembrolizumab. This study will also evaluate the effects of the combination of the peptide vaccine and pembrolizumab on the immune system. The investigators will monitor these effects by performing tests in t...
What is the current status of trial NCT02515227?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2016-10-06. Estimated completion is 2020-03-14.
What interventions are being tested in trial NCT02515227?
The interventions under investigation include: Pembrolizumab (DRUG), 6MHP (BIOLOGICAL).
Who is sponsoring clinical trial NCT02515227?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.